Medical Weight Loss for Memphis, Tennessee Residents

Memphis, Tennessee residents get physician-supervised weight loss by telehealth from New Hope Weight Loss: a $119 doctor review, then compounded semaglutide from $166/month or tirzepatide from $233/month.

Physician-supervised GLP-1 programs from $166/month, serving Memphis through telehealth from our Costa Mesa, California clinic. Doctor review $119. Over 5,400 patients treated.

No clinic to drive to in Memphis: Dr. Anjmun Sharma reviews your health by video, and your compounded semaglutide or tirzepatide ships straight to your Tennessee address. Nothing to pick up, no waiting room, no local office needed. Doctor review just $119 (medication separate).

Why Memphis Residents Choose New Hope Weight Loss

Trust comes down to who is responsible and whether the price is straight, and on both counts New Hope gives Memphis a clear answer. Dr. Anjmun Sharma, MD personally oversees your care, the pricing is flat and posted, and the whole program reaches you by telehealth from Costa Mesa with no insurance required and no distance surcharge. A named physician, an honest number, and care that comes to you across Tennessee. That is the entire promise, and we keep it.

Memphis is served through telehealth from our Costa Mesa, California clinic. The full program runs by secure video, with compounded medication shipped to your Memphis address.

If you are searching for a weight-loss physician in Memphis, the honest answer is that ours is in Costa Mesa, and thanks to telehealth that puts Tennessee patients exactly where local ones are. We care for patients throughout Downtown, Midtown, Cooper-Young, East Memphis, and the greater Memphis area. Your plan is shaped around your own history, the medications you have tried, and the goals you bring, not a one-size template applied to every Memphis patient.

You can start this week from anywhere in Tennessee, because telehealth removes the drive, the parking, and the weeks of waiting that a local clinic would require. We accept HSA and FSA cards for the $119 physician review, which lets many Memphis patients use pre-tax dollars toward their care. Tennessee is one of the fastest-growing states in the South, and New Hope Weight Loss serves patients across it entirely by telehealth from our Costa Mesa, California clinic.

GLP-1 Weight Loss Programs Available

Semaglutide (90-Day Metabolic Reset)

From $166/mo, or $499 for 90 days, our reset program is the route most people in Memphis choose. Semaglutide is the same active ingredient found in Wegovy and Ozempic, and branded-drug studies reported 15 to 17 percent average body-weight loss. Dr. Sharma reviews your dose monthly. Keep in mind that compounded semaglutide is not FDA-approved, is not brand-identical, and that results vary.

Tirzepatide (Dual-Action Program)

From $233/mo, tirzepatide adds a second mechanism, GIP, on top of GLP-1. In clinical trials of the branded drug, dose-qualified patients reached up to 22.5 percent loss, which is not the typical result. Tirzepatide shares its active ingredient with Mounjaro and Zepbound.

Physician review is $119. Medication billed separately. HSA, FSA, Klarna, and Affirm accepted.

How Telehealth Works for Memphis

The path from curious to treated is short, and it all runs through your screen. People in Memphis start by completing a health-and-weight intake quiz online. Dr. Anjmun Sharma reviews every answer and meets you over secure video, usually within 48 hours, to talk through whether a compounded GLP-1 like semaglutide or tirzepatide fits your goals and history. When she prescribes, a state-licensed 503(a) pharmacy ships the medication to your Memphis home in cold-pack packaging designed to keep it stable. After that, you and Dr. Sharma stay connected through video follow-ups, so your progress is supported from any corner of .

Frequently Asked Questions, Memphis

How does someone in Memphis access New Hope Weight Loss?

Access from Memphis is entirely online. Our one physical clinic stands in Costa Mesa, California, while we serve Memphis, Tennessee through telehealth. To begin, Dr. Anjmun Sharma meets you over secure video, reviews your background, and confirms whether you are eligible for a compounded GLP-1 program.

Is a clinic visit part of the process for Memphis residents?

A clinic visit is never part of it for Memphis. The model is fully telehealth, so your consult, refills, and check-ins happen from home. After Dr. Sharma approves you, medication is shipped to Memphis inside cold-pack packaging designed to maintain a steady temperature during transit.

What are the fees for Memphis patients?

The physician review costs $119. Compounded semaglutide runs from $166 each month, or $499 for the 90-day program, and tirzepatide from $233 each month. Medication is billed on its own. We honor HSA, FSA, Klarna, and Affirm, and Memphis residents are charged no distance surcharge.

What areas of Memphis do you serve?

We serve patients from across Memphis by telehealth, including Downtown, Midtown, Cooper-Young, East Memphis, and the greater Memphis area.

Do I need insurance to be treated as a Memphis patient?

No. We are a cash-pay practice, no insurance, no prior authorization, no surprise bills. A $119 physician visit and compounded semaglutide from $166/month, medication billed separately. HSA, FSA, Klarna, and Affirm are accepted.

Memphis Residents, Get Started Today

Doctor review $119. Semaglutide from $166/mo. Tirzepatide from $233/mo. Medication separate.

Start My Journey →

New Hope Weight Loss | clinic at 1503 South Coast Drive, Suite 322, Costa Mesa, CA 92626 | (657) 837-3342 | Serving Memphis, Tennessee by telehealth. Telehealth availability and eligibility are confirmed during the medical consultation.

Wegovy® and Ozempic® are registered trademarks of Novo Nordisk A/S. Mounjaro® and Zepbound® are registered trademarks of Eli Lilly and Company. New Hope Weight Loss is not affiliated with or endorsed by these companies. Compounded semaglutide and tirzepatide are prepared by licensed U.S. pharmacies and are not FDA-approved, not brand-identical, and not reviewed by the FDA for safety, effectiveness, or quality.